KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2025;39(1):52-56 / www.klinickafarmakologie.cz 56 PŘEHLEDOVÉ ČLÁNKY Rozdíly mezi pohlavími – od farmakologie až po metodologii klinického výzkumu 33. Zhao L, Han G, Zhao Y, et al. Gender Differences in Depression: Evidence From Genetics. Front Genet [Internet]. [citován 23. leden 2025];11. Dostupné z: https://www.frontiersin.org/ journals/genetics/articles/10.3389/fgene.2020.562316/full. 34. Pucci G, Alcidi R, Tap L, et al. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res. 120:34-42. 35. Zhu Z, Yu P, Wu Y, et al. Sex Specific Global Burden of Osteoporosis in 204 Countries and Territories, from 1990 to 2030: An Age-Period-Cohort Modeling Study. J Nutr Health Aging. 27(9):767-774. 36. FDA [Internet]. Drug Trials Snapshots. [citován 5. prosinec 2024]; Dostupné z: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots. 37. Labots G, Jones A, de Visser SJ, et al. Gender differences in clinical registration trials: is there a real problem? Br J Clin Pharmacol. 84(4):700-707. 38. Perera ND, Bellomo TR, Schmidt WM, et al. Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020. The Oncologist. 28(6):510-519. 39. FDA [Internet]. Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs; [citován 28. leden 2025]. Dostupné z: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-and-evaluation-gender-differences-clinical-evaluation-drugs. 40. Smith Z, Botto E, Getz K. Quantifying Diversity and Representation in Pivotal Trials Leading to Marketing Authorization in Europe. Ther Innov Regul Sci. 56(5):795-804. 41. Jin X, Chandramouli C, Allocco B, et al. Women’s Participation in Cardiovascular Clinical Trials From 2010 to 2017. Circulation. 141(7):540-548. 42. Khan SU, Khan MZ, Raghu Subramanian C, et al. Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering Therapies: A Systematic Review. JAMA Netw Open. 3(5):e205202. 43. Curno MJ, Rossi S, Hodges-Mameletzis I, et al. A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies. J Acquir Immune Defic Syndr 1999. 71(2):181-188. 44. Rodríguez-Torres E, González-Pérez MM, Díaz-Pérez C. Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews. Contemp Clin Trials Commun. 23:100829. 45. Goldstein KM, Kung LCY, Dailey SA, et al. Strategies for enhancing the representation of women in clinical trials: an evidence map. Syst Rev. 13(1):2. 46. Berlin JA, Ellenberg SS. Inclusion of women in clinical trials. BMC Med. 7:56. 47. Huang GD, Bull J, Johnston McKee K, et al. Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative. Contemp Clin Trials. 66:74-79. 48. Bierer BE, Meloney LG, Ahmed HR, et al. Advancing the inclusion of underrepresented women in clinical research. Cell Rep Med. 3(4):100553. 49. Shiely F, Rychlíčková J, Kubiak C, et al. Training and education on inclusivity in clinical trials – the SENSITISE project. Trials. 25(1):318. TERMÍN: 19.–21. 6. 2025 MÍSTO KONÁNÍ: PARKHOTEL PLZEŇ (U Borského parku 2 791, Plzeň) Česká společnost klinické farmakologie ČLS JEP, z.s. si Vás dovoluje pozvat na 24. ČESKOU KONFERENCI KLINICKÉ FARMAKOLOGIE 28. ČESKOU KONFERENCI TDM KRAJSKÝ REVMATOLOGICKÝ SEMINÁŘ Vzdělávací akce je pořádána dle Stavovského předpisu ČLK č. 16 Veškeré informace jsou zveřejněny na stránkách konference aktivnisvet.cz a na www.cskf.cz.
RkJQdWJsaXNoZXIy NDA4Mjc=